Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
- Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET
- 管理层将于2024年11月7日星期四上午8:30（东部时间）举行电话会议
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update.
新泽西州FLORHAM PARK，2024年10月28日（环球新闻社）— phathom pharmaceuticals公司（纳斯达克股票代码：PHAT）是一家专注于开发和商业化治疗肠道疾病的新颖药物的生物制药公司，今天宣布将于2024年11月7日星期四上午8:30在互联网上直播，汇报2024年第三季度财务业绩并提供业务更新。
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at . A recording will be available for 90 days following the conclusion of the meeting.
可在phathom网站的“事件与演示”部分查看现场网络直播和有关演示的更多信息。 会议结束后将提供90天的录音。
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company's website at and follow on LinkedIn and X.
关于Phathom制药公司
Phathom Pharmaceuticals是一家专注于开发和销售治疗胃肠疾病的新型药物的生物制药公司。Phathom已获得vonoprazan的独家许可权，它是一种首创性的钾竞争性酸阻滞剂(PCAB)，目前在美国以VOQUEZNA(vonoprazan)片剂的形式上市，用于治疗成年人非侵蚀性GERD相关的胃灼热，成人侵蚀性GERD及相关胃灼热的愈合和保持治愈以及VOQUEZNA TRIPLE PAk(vonoprazan片剂、阿莫西林胶囊、克拉霉素片剂)和VOQUEZNA DUAL PAk(vonoprazan片剂、阿莫西林胶囊)用于治疗成人H. pylori感染。有关Phathom的更多信息，请访问公司的网站并关注LinkedIn和X。
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
媒体联系方式
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
投资者联系信息
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
2024年phathom pharmaceuticals保留所有权利。VOQUEZNA，VOQUEZNA DUAL PAk，VOQUEZNA TRIPLE PAk，Phathom Pharmaceuticals及其各自的标志是Phathom Pharmaceuticals，Inc.的注册商标。
译文内容由第三方软件翻译。